Targeting protein kinase-b3 (akt3) signaling in melanoma

References

• Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–7464.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther. 2011;12:1032-1049.
   Web of Science ®Google Scholar
• Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest. 2007;117:719–729.
   PubMed Web of Science ®Google Scholar
• Cho JH, Robinson JP, Arave RA, et al. AKT1 activation promotes development of melanoma metastases. Cell Rep. 2015;13:898–905.
   PubMed Web of Science ®Google Scholar
• Perna D, Karreth FA, Rust AG, et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci U S A. 2015;112:E536–45.
   PubMed Web of Science ®Google Scholar
• Cheung M, Sharma A, Madhunapantula SV, et al. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008;68:3429–3439.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2009;22:400–419.
   PubMed Web of Science ®Google Scholar
• Vredeveld LC, Possik PA, Smit MA, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012;26:1055–1069.
   PubMed Web of Science ®Google Scholar
• Stahl JM, Cheung M, Sharma A, et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003;63:2881–2890.
   PubMed Web of Science ®Google Scholar
• Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64:7002–7010.
   PubMed Web of Science ®Google Scholar
• Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res. 2010;2:19–42.
   PubMed Web of Science ®Google Scholar
• Davies MA, Stemke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008;99:1265–1268.
   PubMed Web of Science ®Google Scholar
• Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102:802–807.
   PubMed Web of Science ®Google Scholar
• Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene. 2005;24:7493–7501.
   PubMed Web of Science ®Google Scholar
• Fayard E, Xue G, Parcellier A, et al. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol. 2010;346:31–56.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.
   PubMedGoogle Scholar
• Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 2007;67:3626–3636.
   PubMed Web of Science ®Google Scholar
• Shi H, Hong A, Kong X, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4:69–79.
   PubMed Web of Science ®Google Scholar
• Kircher DAA, A. R, Cho JH, et al. Melanoma metastases caught in the AKT. Mol Cell Oncol. 2016;3:e1128516. DOI:10.1080/23723556.2015.1128516
   PubMed Web of Science ®Google Scholar
• Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 2005;24:273–285.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–562.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B. Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J. 2000;346:Pt 3, 561–76.
   PubMed Web of Science ®Google Scholar
• Huang J, Bd M. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009;37:217–222.
   PubMed Web of Science ®Google Scholar
• Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Plos Biol. 2009;7:e38.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Peng M, Wang Z, et al. Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol. 2010;30:4280–4292.
   PubMed Web of Science ®Google Scholar
• Wang R, Brattain MG. AKT can be activated in the nucleus. Cell Signal. 2006;18:1722–1731.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Tabellini G, Bressanin D, et al. The emerging multiple roles of nuclear Akt. Biochim Biophys Acta. 2012;1823:2168–2178.
   PubMed Web of Science ®Google Scholar
• Rosner M, Hanneder M, Freilinger A, et al. Nuclear/cytoplasmic localization of Akt activity in the cell cycle. Amino Acids. 2007;32:341–345.
   PubMed Web of Science ®Google Scholar
• Tzivion G, Hay N. PI3K-AKT-FoxO axis in cancer and aging. Biochim Biophys Acta. 2011;1813:1925.
   PubMed Web of Science ®Google Scholar
• Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 2011;1813:1938–1945.
   PubMed Web of Science ®Google Scholar
• Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer. 2009;125:2863–2870.
   PubMed Web of Science ®Google Scholar
• Amiri KI, Richmond A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev. 2005;24:301–313.
   PubMed Web of Science ®Google Scholar
• Ogawara Y, Kishishita S, Obata T, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem. 2002;277:21843–21850.
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–241.
   PubMed Web of Science ®Google Scholar
• Masters SC, Yang H, Datta SR, et al. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol. 2001;60:1325–1331.
   PubMed Web of Science ®Google Scholar
• Zhou H, Li XM, Meinkoth J, et al. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol. 2000;151:483–494.
   PubMed Web of Science ®Google Scholar
• Bd M, Lc C. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274.
   PubMed Web of Science ®Google Scholar
• Kim AH, Khursigara G, Sun X, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001;21:893–901.
   PubMed Web of Science ®Google Scholar
• Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene. 2005;24:7391–7393.
   PubMed Web of Science ®Google Scholar
• Khosravi S, Wong RP, Ardekani GS, et al. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. Br J Cancer. 2014;110:399–408.
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–644.
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.
   PubMed Web of Science ®Google Scholar
• Xu M, Mo YY. The Akt-associated microRNAs. Cell Mol Life Sci. 2012;69:3601–3612.
   PubMed Web of Science ®Google Scholar
• Kim MS, Jeong EG, Yoo NJ, et al. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer. 2008;98:1533–1535.
   PubMed Web of Science ®Google Scholar
• Ivanov AA, Khuri FR, Fu H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci. 2013;34:393–400.
   PubMed Web of Science ®Google Scholar
• Hu H, Goltsov A, Bown JL, et al. Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. Cell Signal. 2013;25:26–32.
   PubMed Web of Science ®Google Scholar
• Han S, Ritzenthaler JD, Zheng Y, et al. PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol. 2008;294:L1238–49.
   PubMed Web of Science ®Google Scholar
• Lee MS, Jeong MH, Lee HW, et al. PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. Nat Commun. 2015;6:7769.
   PubMed Web of Science ®Google Scholar
• Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27:6473–6488.
   PubMed Web of Science ®Google Scholar
• Aziz SA, Davies M, Pick E, et al. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res. 2009;15:3029–3036.
   PubMed Web of Science ®Google Scholar
• Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001;98:10983–10985.
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381–395.
   PubMed Web of Science ®Google Scholar
• Marone R, Cmiljanovic V, Giese B, et al. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008;1784:159–185.
   PubMed Web of Science ®Google Scholar
• Aziz SA, Jilaveanu LB, Zito C, et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res. 2010;16:6029–6039.
   PubMed Web of Science ®Google Scholar
• Werzowa J, Koehrer S, Strommer S, et al. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol. 2011;131:495–503.
   PubMed Web of Science ®Google Scholar
• Tachiiri S, Sasai K, Oya N, et al. Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses. Jpn J Cancer Res. 2000;91:1314–1318.
   PubMedGoogle Scholar
• Harfouche R, Basu S, Soni S, et al. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis. 2009;12:325–338.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329–341.
   PubMed Web of Science ®Google Scholar
• Sweetlove M, Wrightson E, Kolekar S, et al. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front Oncol. 2015;5:135.
   PubMed Web of Science ®Google Scholar
• Lue H, Thiele M, Franz J, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007;26:5046–5059.
   PubMed Web of Science ®Google Scholar
• Oliveira CS, De Bock CE, Molloy TJ, et al. Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer. 2014;14:630.
   PubMed Web of Science ®Google Scholar
• Tanese K, Hashimoto Y, Berkova Z, et al. Cell surface CD74–MIF interactions drive melanoma survival in response to interferon-γ. J Invest Dermatol. 2015;135:2901.
   PubMed Web of Science ®Google Scholar
• Zhao B, Shah P, Budanov AV, et al. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells. J Biol Chem. 2014;289:35806–35814.
   PubMed Web of Science ®Google Scholar
• Budanov AV. Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid Redox Signal. 2011;15:1679–1690.
   PubMed Web of Science ®Google Scholar
• Bae SH, Sung SH, Oh SY, et al. Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab. 2013;17:73–84.
   PubMed Web of Science ®Google Scholar
• Qu CK. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Research. 2000;10:279–288.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang F, Niu R. Functions of Shp2 in cancer. J Cell Mol Med. 2015;19:2075–2083.
   PubMed Web of Science ®Google Scholar
• Zhang RY, Yu ZH, Zeng L, et al. SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget. 2016;7:73817-73829.
   Web of Science ®Google Scholar
• Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–67.
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947.
   PubMed Web of Science ®Google Scholar
• Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet. 2002;70:829–844.
   PubMed Web of Science ®Google Scholar
• Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99:323–334.
   PubMed Web of Science ®Google Scholar
• Maehama T, Je D. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999;9:125–128.
   PubMed Web of Science ®Google Scholar
• Gericke A, Munson M, Ross AH. Regulation of the PTEN phosphatase. Gene. 2006;374:1–9.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Robertson GP. Therapeutic implications of targeting AKT signaling in melanoma. Enzyme Res. 2011;2011:1–20.
   Google Scholar
• Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954–2963.
   PubMed Web of Science ®Google Scholar
• Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006;241:184–196.
   PubMed Web of Science ®Google Scholar
• Stewart AL, Mhashilkar AM, Yang XH, et al. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002;8:451–461.
   PubMed Web of Science ®Google Scholar
• Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research. 2004;64:7002–7010.
   PubMed Web of Science ®Google Scholar
• Wick W, Furnari FB, Naumann U, et al. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene. 1999;18:3936–3943.
   PubMed Web of Science ®Google Scholar
• Nogueira C, Kim KH, Sung H, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 2010;29:6222–6232.
   PubMed Web of Science ®Google Scholar
• Shin SS, Wall BA, Goydos JS, et al. AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res. 2010;23:103–111.
   PubMed Web of Science ®Google Scholar
• Maroulakou IG, Oemler W, Naber SP, et al. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007;67:167–177.
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Polytarchou C, Hatziapostolou M, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal. 2009;2:ra62.
   PubMed Web of Science ®Google Scholar
• Yue J, Huhn S, Shen Z. Complex roles of filamin-A mediated cytoskeleton network in cancer progression. Cell Biosci. 2013;3:7.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Ellinger-Ziegelbauer H, Franzoso G, et al. Physical and functional interaction of filamin (actin-binding protein-280) and tumor necrosis factor receptor-associated factor 2. J Biol Chem. 2000;275:271–278.
   PubMed Web of Science ®Google Scholar
• Maceyka M, Alvarez SE, Milstien S, et al. Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol Cell Biol. 2008;28:5687–5697.
   PubMed Web of Science ®Google Scholar
• Campos LS, Rodriguez YI, Leopoldino AM, et al. Filamin A expression negatively regulates sphingosine-1-phosphate-induced NF-κB activation in melanoma cells by inhibition of Akt signaling. Mol Cell Biol. 2015;36:320–329.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Hengst J, Gowda R, et al. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 2012;25:259–274.
   PubMed Web of Science ®Google Scholar
• Bastians H, Krebber H,Vetrie D, et al. Localization of the novel serine/threonine protein phosphatase 6 gene (PPP6C) to human chromosome Xq22.3. Genomics. 1997;41:296–297.
   PubMed Web of Science ®Google Scholar
• Hammond D, Zeng K., Espert A, et al. Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A. J Cell Sci. 2013;126:3429–3440.
   PubMed Web of Science ®Google Scholar
• Hayashi K MY, Momoi Y, Tanuma N, et al. Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA. Oncogene. 2015;34:4647–4655.
   PubMed Web of Science ®Google Scholar
• Kovacina KS, Park GY, Bae SS, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189–10194.
   PubMed Web of Science ®Google Scholar
• Wiza C, Nascimento EB, Ouwens DM. Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab. 2012;302:E1453–60.
   PubMed Web of Science ®Google Scholar
• Nascimento EB, Ouwens DM. PRAS40: target or modulator of mTORC1 signalling and insulin action? Arch Physiol Biochem. 2009;115:163–175.
   PubMedGoogle Scholar
• Havel JJ, Li Z, Cheng D, et al. Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. Oncogene. 2015;34:1487–1498.
   PubMed Web of Science ®Google Scholar
• Kardos GR, Wastyk HC, Robertson GP. Disruption of proline synthesis in melanoma inhibits protein production mediated by the GCN2 pathway. Mol Cancer Res. 2015;13:1408–1420.
   PubMed Web of Science ®Google Scholar
• Huang L, Nakai Y, Kuwahara I, et al. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma. Cancer Res. 2012;72:1260–1269.
   PubMed Web of Science ®Google Scholar
• Lv D, Liu J, Guo L, et al. PRAS40 deregulates apoptosis in Ewing sarcoma family tumors by enhancing the insulin receptor/Akt and mTOR signaling pathways. Am J Cancer Res. 2016;6:486–497.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Bertrand FE, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014;5:2881–2911.
   PubMed Web of Science ®Google Scholar
• Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32:577–595.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Sharma A, Gowda R, et al. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2013;26:886–899.
   PubMed Web of Science ®Google Scholar
• Panka DJ, Cho DC, Atkins MB, et al. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008;283:726–732.
   PubMed Web of Science ®Google Scholar
• Bellei B, Flori E, Izzo E, et al. GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal. 2008;20:1750–1761.
   PubMed Web of Science ®Google Scholar
• Kubic JD, Mascarenhas JB, Iizuka T, et al. GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells. Mol Cancer Res. 2012;10:1065–1076.
   PubMed Web of Science ®Google Scholar
• Medic S, Ziman M. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas). Plos One. 2010;5:e9977.
   PubMed Web of Science ®Google Scholar
• Atkinson JM, Rank KB, Zeng Y, et al. Activating the Wnt/β-Catenin pathway for the treatment of melanoma – application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3. Plos One. 2015;10:e0125028.
   PubMed Web of Science ®Google Scholar
• John JK, Paraiso KHT, Rebecca VW, et al. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol. 2012;132:2818–2827.
   PubMed Web of Science ®Google Scholar
• Kao SH, Wang WL, Chen CY, et al. GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene. 2014;33:3172–3182.
   PubMed Web of Science ®Google Scholar
• Bolos V, Gasent JM, Lopez-Tarruella S, et al. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther. 2010;3:83–97.
   PubMed Web of Science ®Google Scholar
• Eldar-Finkelman H, Martinez A. GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci. 2011;4:32.
   PubMed Web of Science ®Google Scholar
• Sharma A, Madhunapantula SV, Gowda R, et al. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol. 2013;182:1151–1162.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Schmitz U, Wolkenhauer O, et al. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene. 2013;32:3175–3183.
   PubMed Web of Science ®Google Scholar
• Vriend LE, De Witt Hamer PC, Van Noorden CJ, et al. WEE1 inhibition and genomic instability in cancer. Biochim Biophys Acta. 2013;1836:227–235.
   PubMed Web of Science ®Google Scholar
• Magnussen GI, Emilsen E, Giller Fleten K, et al. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer. 2015;15:462.
   PubMed Web of Science ®Google Scholar
• Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013;12:3159–3164.
   PubMed Web of Science ®Google Scholar
• Katayama K, Fujita N, Tsuruo T. Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol. 2005;25:5725–5737.
   PubMed Web of Science ®Google Scholar
• Ghiasi N, Habibagahi M, Rosli R, et al. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells. Asian Pac J Cancer Prev. 2014;14:6605–6611.
   PubMedGoogle Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954.
   PubMed Web of Science ®Google Scholar
• Gs I, Sv M, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010;80:624–637.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 2008;68:5–8.
   PubMed Web of Science ®Google Scholar
• Guan KL, Figueroa C, Brtva TR, et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem. 2000;275:27354–27359.
   PubMed Web of Science ®Google Scholar
• Dhomen N, Reis-Filho JS, Da Rocha Dias S. et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15:294–303.
   PubMed Web of Science ®Google Scholar
• Madhunapantula SV, Desai D, Sharma A, et al. PBIse, a novel selenium containing drug for the treatment of malignant melanoma. Mol Cancer Ther. 2008;7:1297–1308.
   PubMed Web of Science ®Google Scholar
• Gowda R, Madhunapantula SV, Desai D, et al. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther. 2013;12:3–15.
   PubMed Web of Science ®Google Scholar
• Gowda R, Madhunapantula SV, Desai D, et al. Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther. 2012;13:756–765.
   PubMed Web of Science ®Google Scholar
• Hong SK, Jeong JH, Chan AM, et al. AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Exp Cell Res. 2013;319:1732–1743.
   PubMed Web of Science ®Google Scholar
• Peres J, Mowla S, Prince S. The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis. Oncotarget. 2015;6:1821–1833.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Aladowicz E, Lanfrancone L, et al. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res. 2008;68:7872–7881.
   PubMed Web of Science ®Google Scholar
• Peres J, Davis E, Mowla S, et al. The highly homologous t-box transcription factors, TBX2 and TBX3, have distinct roles in the oncogenic process. Genes Cancer. 2010;1:272–282.
   PubMedGoogle Scholar
• Abraham AG, O’Neill E. PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans. 2014;42:798–803.
   PubMed Web of Science ®Google Scholar
• Vadlakonda L, Pasupuleti M, Pallu R. Role of PI3K-AKT-mTOR and Wnt signaling pathways in transition of G1-S phase of cell cycle in cancer cells. Front Oncol. 2013;3:85.
   PubMedGoogle Scholar
• Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8:1153–1160.
   PubMed Web of Science ®Google Scholar
• Rossig L, Jadidi AS, Urbich C, et al. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol. 2001;21:5644–5657.
   PubMed Web of Science ®Google Scholar
• Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst. 2013;105:393–404.
   PubMedGoogle Scholar
• Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012;18:142–147.
   PubMed Web of Science ®Google Scholar
• Zhu QS, Rosenblatt K, Huang KL, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011;30:457–470.
   PubMed Web of Science ®Google Scholar
• Lin HK, Wang G, Chen Z, et al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009;11:420–432.
   PubMed Web of Science ®Google Scholar
• McKenzie JA, Liu T, Goodson AG, et al. Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res. 2010;70:7927–7937.
   PubMed Web of Science ®Google Scholar
• Liu P, Hu Y, Ma L, et al. miR-425 inhibits melanoma metastasis through repression of PI3K-Akt pathway by targeting IGF-1. Biomed Pharmacother. 2015;75:51–57.
   PubMed Web of Science ®Google Scholar
• Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol. 2007;34:555–565.
   PubMed Web of Science ®Google Scholar
• Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 2009;102:19–65.
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605.
   PubMed Web of Science ®Google Scholar
• Pore N, Jiang Z, Shu HK, et al. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res. 2006;4:471–479.
   PubMed Web of Science ®Google Scholar
• Yang GW, Jiang JS, Lu WQ. Ferulic acid exerts anti-angiogenic and anti-tumor activity by targeting fibroblast growth factor receptor 1-mediated angiogenesis. Int J Mol Sci. 2015;16:24011–24031.
   PubMed Web of Science ®Google Scholar
• Graells J, Vinyals A, Figueras A, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 2004;123:1151–1161.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Yoneta A, Hida T. Macrophage inhibitory cytokine-1: a new player in melanoma development. J Invest Dermatol. 2009;129:262–264.
   PubMed Web of Science ®Google Scholar
• Kim KK, Lee JJ, Yang Y, et al. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis. 2008;29:704–712.
   PubMed Web of Science ®Google Scholar
• Huh SJ, Chung CY, Sharma A, et al. Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol. 2010;176:2948–2957.
   PubMed Web of Science ®Google Scholar
• Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39:347–354.
   PubMed Web of Science ®Google Scholar
• Kamenisch Y, Baban TS, Schuller W, et al. UVA-irradiation induces melanoma invasion via enhanced Warburg effect. J Invest Dermatol. 2016;136:1866–1875.
   PubMed Web of Science ®Google Scholar
• Rathmell JC, Fox CJ, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003;23:7315–7328.
   PubMed Web of Science ®Google Scholar
• Novellasdemunt L, Tato I, Navarro-Sabate A, et al. Akt-dependent activation of the heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB2) isoenzyme by amino acids. J Biol Chem. 2013;288:10640–10651.
   PubMed Web of Science ®Google Scholar
• Rashmi R, DeSelm C, Helms C, et al. AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. Plos One. 2014;9:e92948.
   PubMed Web of Science ®Google Scholar
• Hambright HG, Meng P, Kumar AP, et al. Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget. 2015;6:7195–7208.
   PubMed Web of Science ®Google Scholar
• Kumar R, Das M, Ansari KM. Nexrutine(R) inhibits tumorigenesis in mouse skin and induces apoptotic cell death in human squamous carcinoma A431 and human melanoma A375 cells. Carcinogenesis. 2012;33:1909–1918.
   PubMed Web of Science ®Google Scholar
• Cheng JQ, Lindsley CW, Cheng GZ, et al. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005;24:7482–7492.
   PubMed Web of Science ®Google Scholar
• Howell PM Jr., Li X, Riker AI, et al. MicroRNA in melanoma. Ochsner J. 2010;10:83–92.
   PubMedGoogle Scholar
• Yan D, Dong XD, Chen X, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. Plos One. 2012;7:e40967.
   PubMed Web of Science ®Google Scholar
• Misso G, Di Martino MT, De Rosa G, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194.
   PubMedGoogle Scholar
• Zhou CH, Zhang XP, Liu F, et al. Involvement of miR-605 and miR-34a in the DNA damage response promotes apoptosis induction. Biophys J. 2014;106:1792–1800.
   PubMed Web of Science ®Google Scholar
• Cui SY, Wang R, Chen LB. MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18:1913–1926.
   PubMed Web of Science ®Google Scholar
• Li Y, Huang Q, Shi X, et al. MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1. Chin Med J (Engl). 2014;127:1410–1416.
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Quintavalle C, Romano G, et al. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012;12:27–33.
   PubMed Web of Science ®Google Scholar
• Palacios F, Abreu C, Prieto D, et al. Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia. 2015;29:115–125.
   PubMed Web of Science ®Google Scholar
• Tan G, Shi Y, Wu ZH. MicroRNA-22 promotes cell survival upon UV radiation by repressing PTEN. Biochem Biophys Res Commun. 2012;417:546–551.
   PubMed Web of Science ®Google Scholar
• Shelledy L, Vemurafenib: RD. First-in-class BRAF-mutated inhibitor for the treatment of unresectable or metastatic melanoma. J Adv Pract Oncol. 2015;6:361–365.
   PubMedGoogle Scholar
• Hagen B, Trinh VA. Managing side effects of vemurafenib therapy for advanced melanoma. J Adv Pract Oncol. 2014;5:400–410.
   PubMedGoogle Scholar
• Kugel CH 3rd, Aplin AE. Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell Melanoma Res. 2014;27:1032–1038.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71:7137–7140.
   PubMed Web of Science ®Google Scholar
• Choi J, Landrette SF, Wang T, et al. Identification of PLX4032 resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014;27:253–262.
   PubMed Web of Science ®Google Scholar
• Manzano JL, Layos L, Buges C, et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016;4:237.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977.
   PubMed Web of Science ®Google Scholar
• Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
   PubMed Web of Science ®Google Scholar
• Lassen A, Atefi M, Robert L, et al. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 2014;13:83.
   PubMed Web of Science ®Google Scholar
• Tran MA, Smith CD, Kester M, et al. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res. 2008;14:3571–3581.
   PubMed Web of Science ®Google Scholar
• Tran MA, Gowda R, Sharma A, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 2008;68:7638–7649.
   PubMed Web of Science ®Google Scholar
• Dumble M, Crouthamel MC, Zhang SY, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. Plos One. 2014;9:e100880.
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8:48–56.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389–1398.
   PubMed Web of Science ®Google Scholar
• Chen B, Tardell C, Higgins B, et al. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. Plos One. 2012;7:e42598.
   PubMed Web of Science ®Google Scholar
• Fang X, Yu S, Eder A, et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999;18:6635–6640.
   PubMed Web of Science ®Google Scholar
• Eisenmann KM, VanBrocklin MW, Staffend NA, et al. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res. 2003;63:8330–8337.
   PubMed Web of Science ®Google Scholar
• Douglas BJ, Flaherty. KT, Weber JS, et al. Combined BRAF (dabrafenib) and MEK inhibition (tramatinib) in patients with BRAFV600E mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014;32:3697–3704.
   PubMed Web of Science ®Google Scholar
• Jsg EM-C, Perez-Garcia JM, et al. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl Med. 2015;3:207.
   PubMedGoogle Scholar
• Ascierto P, Simeone E, Sileni VC, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the italian cohort of the ipilimumab expanded access program. Cancer Invest. 2014;32:144–149.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, S E, Giannarelli D, et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Trans Med. 2012;10:1–8.
   PubMed Web of Science ®Google Scholar
• Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112:1421–1427.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97–106.
   PubMed Web of Science ®Google Scholar